全文获取类型
收费全文 | 482篇 |
免费 | 52篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 17篇 |
妇产科学 | 35篇 |
基础医学 | 86篇 |
口腔科学 | 11篇 |
临床医学 | 33篇 |
内科学 | 94篇 |
皮肤病学 | 6篇 |
神经病学 | 29篇 |
特种医学 | 70篇 |
外科学 | 25篇 |
综合类 | 17篇 |
预防医学 | 35篇 |
眼科学 | 5篇 |
药学 | 24篇 |
肿瘤学 | 58篇 |
出版年
2022年 | 2篇 |
2021年 | 6篇 |
2019年 | 3篇 |
2018年 | 5篇 |
2017年 | 8篇 |
2016年 | 11篇 |
2015年 | 11篇 |
2014年 | 12篇 |
2013年 | 12篇 |
2012年 | 23篇 |
2011年 | 14篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 15篇 |
2007年 | 21篇 |
2006年 | 21篇 |
2005年 | 12篇 |
2004年 | 12篇 |
2003年 | 12篇 |
2002年 | 8篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 17篇 |
1998年 | 29篇 |
1997年 | 18篇 |
1996年 | 16篇 |
1995年 | 17篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 11篇 |
1991年 | 8篇 |
1990年 | 17篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 7篇 |
1985年 | 11篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 6篇 |
1969年 | 3篇 |
1968年 | 2篇 |
1966年 | 3篇 |
排序方式: 共有547条查询结果,搜索用时 15 毫秒
61.
A monoclonal antibody-defined membrane antigen complex is required for neutrophil-neutrophil aggregation 总被引:7,自引:0,他引:7
We examined the aggregation responses of normal neutrophils treated with the murine monoclonal antibody (MoAb) 60.3. Addition of MoAb 60.3 to normal neutrophils produced dose-dependent inhibition of neutrophil aggregation in response to phorbol myristate acetate, zymosan-activated plasma, and N-formyl-methionylleucylphenylalanine. We conclude that the membrane glycoprotein complex recognized by MoAb 60.3--designated CDw18- -is required for neutrophil-neutrophil aggregation in vitro. 相似文献
62.
63.
64.
65.
Tomohisa Okada Thai Akasaka Dinh HD Thuy Tadashi Isa 《Magnetic resonance in medical sciences》2022,21(4):531
After introduction of the first human 7 tesla (7T) system in 1999, 7T MR systems have been employed as one of the most advanced platforms for human MR research for more than 20 years. Currently, two 7T MR models are approved for clinical use in the U.S.A. The approval facilitated introduction of the 7T system, summing up to around 100 worldwide. The approval in Japan is much awaited. As a clinical MR scanner, the 7T MR system is drawing attention in terms of safety.Several large-sized studies on bioeffects have been reported for vertigo, dizziness, motion disturbances, nausea, and others. Such effects might also be found in MR workers and researchers. Frequency and severity of reported bioeffects will be presented and discussed, including their variances. The high resonance frequency and shorter RF wavelength of 7T increase the concern about the safety. Homogeneous RF pulse excitation is difficult even for the brain, and a multi-channel parallel transmit (pTx) system is considered mandatory. However, pTx may create a hot spot, which makes the estimation of specific absorption rate (SAR) to be difficult. The stronger magnetic field of 7T causes a large force of displacement and heating on metallic implants or devices, and the scan of patients with them should not be conducted at 7T. However, there are some opinions that such patients might be scanned even at 7T, if certain criteria are met. This article provides a brief review on the effect of the static magnetic field on humans (MR subjects, workers, and researchers) and neurons, in addition to scan sound, SAR, and metal implants and devices. Understanding and avoiding adverse effects will contribute to the reduction in safety risks and the prevention of incidents. 相似文献
66.
Michelle F Green Catherine H Watson Sarah Tait Jie He Dean C Pavlick Garrett Frampton Jinny Riedel Jennifer K Plichta Andrew J Armstrong Rebecca A Previs Noah Kauff John H Strickler Michael B Datto Andrew Berchuck Carolyn S Menendez 《The oncologist》2023,28(1):33
ObjectiveThe majority of tumor sequencing currently performed on cancer patients does not include a matched normal control, and in cases where germline testing is performed, it is usually run independently of tumor testing. The rates of concordance between variants identified via germline and tumor testing in this context are poorly understood. We compared tumor and germline sequencing results in patients with breast, ovarian, pancreatic, and prostate cancer who were found to harbor alterations in genes associated with homologous recombination deficiency (HRD) and increased hereditary cancer risk. We then evaluated the potential for a computational somatic-germline-zygosity (SGZ) modeling algorithm to predict germline status based on tumor-only comprehensive genomic profiling (CGP) results.MethodsA retrospective chart review was performed using an academic cancer center’s databases of somatic and germline sequencing tests, and concordance between tumor and germline results was assessed. SGZ modeling from tumor-only CGP was compared to germline results to assess this method’s accuracy in determining germline mutation status.ResultsA total of 115 patients with 146 total alterations were identified. Concordance rates between somatic and germline alterations ranged from 0% to 85.7% depending on the gene and variant classification. After correcting for differences in variant classification and filtering practices, SGZ modeling was found to have 97.2% sensitivity and 90.3% specificity for the prediction of somatic versus germline origin.ConclusionsMutations in HRD genes identified by tumor-only sequencing are frequently germline. Providers should be aware that technical differences related to assay design, variant filtering, and variant classification can contribute to discordance between tumor-only and germline sequencing test results. In addition, SGZ modeling had high predictive power to distinguish between mutations of somatic and germline origin without the need for a matched normal control, and could potentially be considered to inform clinical decision-making.This study sought to describe concordance between germline and tumor testing among patients at the investigators'' institution and queried whether results from one test type could be used to inform the other. The authors also investigated the potential of a computational modeling algorithm to predict germline status based on tumor-only comprehensive genomic profiling results alone.Implications for PracticeThe majority of tumor sequencing currently performed on cancer patients does not include a matched normal control, and in cases where germline testing is performed, it is usually run independently of tumor testing. The rates of concordance between variants identified via germline and tumor testing in this context are poorly understood. This study found that mutations in cancer predisposing genes identified by tumor-only sequencing are frequently germline, but providers should be aware that technical differences related to assay design, variant filtering, and variant classification can contribute to discordance between tumor-only and germline sequencing test results. In addition, computational somatic-germline-zygosity (SGZ) modeling had high predictive power to distinguish between mutations of somatic and germline origin without the need for a matched normal control, and could potentially be considered to inform clinical decision-making. 相似文献
67.
68.
L M Weiss J G Strickler L J Medeiros J Gerdes H Stein R A Warnke 《Human pathology》1987,18(11):1155-1159
The Ki-67 antibody, a monoclonal antibody that reacts with nuclei in actively proliferating cells, was used in an immunohistochemical study to assess the growth fractions of non-Hodgkin's lymphomas and related disorders. The lowest proliferative indices were found in small lymphocytic lymphoma/chronic lymphocytic leukemia and intermediate lymphocytic/mantle zone lymphoma. An intermediate proliferative index was seen in the follicular lymphomas and diffuse small cleaved cell and diffuse mixed cell lymphomas. A high index was seen in the diffuse large cell lymphoma and lymphoblastic lymphoma. The highest and most consistent proliferative index was seen in small noncleaved cell lymphoma. Cases of reactive follicular hyperplasia had a significantly higher proliferative index than those of follicular lymphoma. We conclude that the Ki-67 antibody has great utility in providing an estimate of the proliferative rate of non-Hodgkin's lymphomas. Prospective studies may show this information to have prognostic value independent of histologic classification. 相似文献
69.
Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. 总被引:4,自引:2,他引:2
van Rensburg CJ Honiball PJ Grundling HD van Zyl JH Spies SK Eloff FP Simjee AE Segal I Botha JF Cariem AK Marks IN Theron I Bethke TD 《Alimentary pharmacology & therapeutics》1996,10(3):397-401
BACKGROUND: Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+- ATPase. METHODS: Pantoprazole 40 mg and 80 mg were compared in a randomized double-blind study in 192 out-patients with stage II or III (Savary-Miller classification) reflux oesophagitis. Patients received either pantoprazole 40 mg (n = 97) or pantoprazole 80 mg (n = 95), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the oesophagitis had not healed. RESULTS: After 4 weeks complete healing of the reflux oesophagitis was seen in 78% of protocol-correct patients given pantoprazole 40 mg daily (n = 86), and in 72% in the 80 mg (n = 87) group. The cumulative healing rates after 8 weeks were 95 and 94%, respectively (P > 0.05, Cochran-Mantel- Haenszel), and time until healing of oesophagitis comparable in both groups. Differences between doses were also not significant in an intention-to-treat analysis. Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief. No adverse event or changes in laboratory values of clinical significance could definitely be ascribed to the trial medication. CONCLUSION: The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability. 相似文献
70.
高效液相色谱法测定人血清和尿中盐酸青藤碱浓度及药代动力学研究 总被引:15,自引:0,他引:15
用RP-HPLC法,以三唑仑为内标,反相C18为分析柱,乙腈—0.01mol·L-1磷酸二氢钠—四甲基乙二胺(46∶54∶0.22v/v)为流动相,磷酸调至pH6.9,检测波长263nm,测定血清和尿中盐酸青藤碱浓度,线性范围分别为6~480ng·mL-1和0.06~3μg·mL-1,平均回收率75.88%和91.35%,日内日间误差小于5%,最低检测浓度血清4ng·mL-1,尿40ng·mL-1。8名健康男性志愿者单次口服盐酸青藤碱片80mg,测定血清及尿浓度,该药符合二室开放模型,体内消除符合一级动力学消除过程,主要药代动力学参数:T1/2α0.791±0.491h,T1/2β9.397±2.425h,Tmax 1.040±0.274h,Cmax246.604±71.165ng·mL-1,AUC 2651.158±1039.050ng·h·mL-1,CL 0.033±0.01ng·mL-1。 相似文献